Detail akcie enVVeno Medical Rg online

Business Summary: enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Financial Summary: BRIEF: For the six months ended 30 June 2025, enVVeno Medical Corp revenues was not reported. Net loss increased 13% to $11.2M. Higher net loss reflects Selling/General/Admin. Expense increase of 58% to $4.2M (expense), Unrealized gain (loss) from trading secu decrease from $90K (income) to $273K (expense), Realized gains from sales of trading sec decrease of 16% to $665K (income).